Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
human blood coagulation factor VIII
CSL Behring GmbH
B02BD02
human blood coagulation factor VIII
500IU
powder and solvent for solution for injection/ infusion
(1) glass vial, (1) solvent in glass vial 5ml, (1) filter transfer device 20/20
Prescription
Registered
2020-09-05
REG-5487-02 WHAT IS IN THIS LEAFLET: 1. What Beriate 500 is and what it is used for 2. What you need to know before you use Beriate 500 3. How to use Beriate 500 4. Possible side effects 5. How to store Beriate 500 6. Contents of the pack and other information 1. WHAT BERIATE 500 IS AND WHAT IT IS USED FOR WHAT IS BERIATE 500? Beriate 500 is a powder plus the solvent. The made up solution is to be given by injection or infusion into a vein. Beriate 500 is made from human plasma (this is the liquid part of the blood) and it contains human coagulation Factor VIII. It is used to prevent or to stop bleedings caused by the lack of Factor VIII (haemophilia A) in the blood. It may also be used in the management of acquired Factor VIII deficiency. WHAT IS BERIATE 500 USED FOR? Factor VIII is involved in blood clotting (coagulation). Lack of Factor VIII means that blood does not clot as quickly as it should and so there is an increased tendency to bleed. The replacement of Factor VIII with Beriate 500 will temporarily repair the coagulation mechanisms. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE BERIATE 500 The following sections contain information that you and your doctor should consider before you use Beriate 500. DO NOT USE BERIATE 500: • If you are allergic (hypersensitive) to the human coagulation factor VIII or to any of the ingredients of this medicine (listed in section 6.). WARNINGS AND PRECAUTIONS: Talk to your doctor or pharmacist before using Beriate 500. • Allergic type hypersensitivity reactions are possible. Your doctor should inform you of the EARLY SIGNS OF HYPERSENSITIVITY REACTIONS. These include hives, generalised skin rash, tightness of the chest, wheezing, fall in blood pressure and anaphylaxis (a serious allergic reaction that causes severe difficulty in breathing, or dizziness). IF THESE SYMPTOMS OCCUR, YOU SHOULD STOP THE USE OF THE PRODUCT IMMEDIATELY AND CONTACT YOUR DOCTOR. • The formation of INHIBITORS (neutralising antibodies) to Factor VIII is a known complication that can occur during tr Read the complete document
CSL Behring Page 1 of 13 Beriate_Data Sheet-UNE-EN_05-Aug-2022_blank MULTI MARKET MANUSCRIPT DATA SHEET – DS/UNE/EN BERIATE ® 250/500/1000 REVISION DATE: 05-AUG-2022 REASON FOR CHANGE: CCDS V12.0 UPDATE: FREQUENCY OF FVIII INHIBITION Supersedes previous versions Revision date: 04-OCT-2021 / Introduction of administration pack Rev.: 23-AUG-2019 / Pharmaceutical Particulars - Method of administration/General instructions update Rev.: 26-JUL-2016 / Section 2 update specific activity / section 4.8 CCSI editorial update CSL BEHRING BERIATE ® 250/500/1000 MULTI MARKET DS/UNE/EN, REV.: 05-AUG-2022 / CCDS V12.0 UPDATE: FREQUENCY OF FVIII INHIBITION CSL Behring Page 2 of 13 Beriate_Data Sheet-UNE-EN_05-Aug-2022_blank 1. NAME OF THE MEDICINAL PRODUCT Beriate Powder and solvent for solution for injection or infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains nominally: 250/500/1000 IU human coagulation factor VIII (FVIII). After reconstitution with 2.5/5/10 ml Beriate 250/500/1000 contains 100 IU/ml factor VIII. The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The mean specific activity of Beriate is approximately 400 IU/mg protein. Excipient with known effect: Sodium approximately 100 mmol/l (2.3 mg/ml). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection or infusion. White powder and clear, colourless solvent for solution for injection/infusion. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). This product may be used in the management of acquired factor VIII deficiency. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia. _POSOLOGY _ The dosage and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on th Read the complete document